Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds

Dow Jones2021-11-22

Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.

The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile "was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose."

BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • Jules_Huat
    2021-11-23
    Jules_Huat
    Hmmm ok...
  • 小小仙女
    2021-11-23
    小小仙女
    Like
  • 小小仙女
    2021-11-23
    小小仙女
    Tell me your opinion about this news...
    • MengKeng
      it is good for little children who can be vaccinated and also people who hold Pfizer shares, haha
  • koolgal
    2021-11-23
    koolgal
    Pfizer & BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay.  Share prices of these 2 companies will also rise in tandem!  Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙
  • Dawang
    2021-11-22
    Dawang
    Time to protect our young tooo.;) Then travelling can truly take place.
  • MHh
    2021-11-22
    MHh
    As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…
发表看法
18